Amersham will supply its Streamline expanded bed technology to GCC, and upon completion of the first stage of the facility, the production capacity will reach 12.5 metric tons of pure rHSA per year. * BioChem Pharma Inc., of Laval, Quebec, said its licensee, Glaxo Wellcome plc, of London, filed for marketing approval in the European Union for lamivudine for chronic hepatitis B. The drug has shown positive Phase III trial results against hepatitis B. (See BioWorld Today, April 11, 1997, p. 1

Biochem Pharma Inc., of Laval, Quebec, said its licensee, Glaxo Wellcome plc, of London, received approval from the European Commission to market Combivir in the 15 member states of the European Union (EU

EpiGenesis plans to use the funds for development of its lead compound, Epi 2010, a respirable antisense oligonucleotide drug to reduce inflammation and bronchoconstriction...Terms were not disclosed. * MGI Pharma Inc., of Minneapolis, won FDA approval of Salagen Tablets (pilocarpine HCl) as a treatment for dry mouth resulting from Sjögren's syndrome

The only other imminent biotech IPO — by Montreal-based RTP Pharma Inc. — had been scheduled for December but was instead postponed due to market conditions, according to president and CEO Gary Pace

Oros is an osmotic controlled-release system designed for fewer administrations of drugs. * BioChem Pharma Inc., of Laval, Quebec, said its partner, Glaxo Wellcome plc., of London, filed for marketing approval of lamivudine for hepatitis B in China...The companies said 300 million to 350 million people worldwide are chronic carriers of hepatitis B and a majority live in Asia. * Chiron Diagnostics, of East Walpole, Mass., reported the U.S

patent on compounds it has under study for the condition. * ImmunoGen Inc., of Cambridge, Mass., and BioChem Pharma Inc., of Laval, Quebec, have inked a collaboration agreement involving BioChem and ImmuGen's 95-percent-owned subsidiary, Apoptosis Technology Inc. (ATI...Upon approval of the IND, Taiho will license rights to Japan and possibly other Asian countries

patent on compounds it has under study for the condition. * ImmunoGen Inc., of Cambridge, Mass., and BioChem Pharma Inc., of Laval, Quebec, have inked a collaboration agreement involving BioChem and ImmuGen's 95 percent-owned subsidiary, Apoptosis Technology Inc...BioChem Therapeutics is a wholly owned subsidiary of BioChem Pharma Inc., of Laval, Quebec

The blinded, placebo-controlled trial will evaluate the vaccine's effectiveness in protecting healthy adults from the infection, which can lead to life-threatening diarrhea. * BioChem Pharma Inc., of Laval, Quebec, changed its NASDAQ National Market symbol to BCHE. * MedImmune Inc., of Gaithersburg, Md., adopted a shareholder rights plan to prevent unwanted takeovers of the company

BioChem Pharma Inc., of Laval, Quebec, declared success and stopped a U.S...BioChem Pharma developed 3TC, whose worldwide marketing rights (except in Canada) belong to Glaxo Wellcome plc, of London

Inteferon Sciences Inc., of New Brunswick, N.J., has reached the enrollment target of 275 patients in its Phase III multicenter, randomized, controlled clinical trial designed to evaluate the safety and efficacy of Alferon N Injection, the company's highly purified, multispecies, natural-source alpha interferon, for the treatment of previously untreated patients infected with hepatitis C virus. * Neuroscience Pharma Inc., of San Diego, has initiated a Phase II/III double-blind, placebo

Drugs for this condition will be developed using the company's access to data on 30,000 twin pairs, who already have been screened for this disorder. * BioChem Pharma Inc., of Laval, Quebec, reported the FDA approved its investigational new drug application to initiate a Phase I trial in the U.S

BioChem Pharma Inc., of Quebec, reported Phase I clinical trial results on a novel cell culture-based influenza vaccine demonstrate it is safe and significantly boosts immunity in healthy volunteers

Each unit consists of one common share and a warrant to purchase another common share. * Vertex Pharmaceuticals Inc., of Cambridge, Mass., and its partner, BioChem Pharma Inc., of Laval, Quebec, began a Phase II trial of the former's VX-710 for breast cancer and soft tissue sarcoma

MGI Pharma Inc., of Minetonka, Minn., finalized an agreement to co-develop the anti-tumor compound MGI 114 with the National Cancer Institute

BioChem Pharma Inc., of Laval, Quebec, entered a collaboration with XTL Biopharmaceuticals, of Rehovot, Israel, for drug discovery aimed a developing treatments for hepatitis C. Financial terms were not disclosed...The agreement gives BioChem Pharma an exclusive two-year license to XTL's Trimera technology for creating models of the infection. * Cel-Sci Corp., of Alexandria, Va., raised $5 million through the sale of convertible stock to institutional investors

Protein Polymer will get an additional $400,000 in the extended agreement. * BioChem Pharma Inc., of Laval, Quebec, entered a collaboration with XTL Biopharmaceuticals, of Rehovot, Israel, for drug discovery aimed a developing treatments for hepatitis C. Financial terms were not disclosed...The agreement gives BioChem Pharma an exclusive two-year license to XTL's Trimera technology for creating models of the infection. * North American Vaccine Inc., of Beltsville, Md., signed an agreement in

Protein Polymer will get an additional $400,000 in the extended agreement. * BioChem Pharma Inc., of Laval, Quebec, entered a collaboration with XTL Biopharmaceuticals, of Rehovot, Israel, for drug discovery aimed a developing treatments for hepatitis C. Financial terms were not disclosed...The agreement gives BioChem Pharma an exclusive two-year license to XTL's Trimera technology for creating models of the infection. * North American Vaccine Inc., of Beltsville, Md., signed an agreement in

The synthetic analogues will be evaluated for their cytoprotective capacity and their cytotoxicity in the cell lines to establish indices for the compounds. * MGI Pharma Inc., of Minnetonka, Minn., said the National Cancer Institute voted in favor of funding and conducting human trials of MGI 114, the lead analogue from MGI's acylfulvene family of anti- cancer compounds

The synthetic analogues will be evaluated for their cytoprotective capacity and their cytotoxicity in the cell lines to establish indices for the compounds. * MGI Pharma Inc., of Minnetonka, Minn., said the National Cancer Institute voted in favor of funding and conducting human trials of MGI 114, the lead analogue from MGI's acylfulvene family of anti- cancer compounds